Informed Managed Care Decision-Making in the Management of Endometrial Cancer: Optimizing Immunotherapy for Improved Patient Outcomes.
Immunotherapy with checkpoint inhibitors has become a promising treatment option for treating advanced endometrial cancer. While initially used in the second-line or later setting, these therapies are being used in combination with standard of care chemotherapy in the first-line treatment setting. I...
| Publicado en: | Journal of Managed Care Medicine Vol. 28; no. 2; pp. 14 - 20 |
|---|---|
| Autor principal: | |
| Formato: | tables/charts Journal Article |
| Publicado: |
National Association of Managed Care Physicians, Inc.
2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Immunotherapy with checkpoint inhibitors has become a promising treatment option for treating advanced endometrial cancer. While initially used in the second-line or later setting, these therapies are being used in combination with standard of care chemotherapy in the first-line treatment setting. Improvements in progression-free survival and overall survival are being shown with immunotherapy/chemotherapy combinations. |
|---|